Lead Asset
MDL-001
A New Paradigm in Antiviral Therapy
An oral, first-in-class, best-in-class pan-antiviral designed to combat multiple viruses with a single treatment, providing a breakthrough solution for global health challenges.
MDL-001 represents a breakthrough in antiviral medicine
New Target Biology
Unlocking the Potential of RdRp Thumb-1
MDL-001 represents a breakthrough in antiviral medicine, targeting the RdRp Thumb-1 cryptic allosteric site—a highly conserved and previously untapped vulnerability critical for viral replication. Unlike traditional approaches that target active sites, this novel mechanism disrupts RNA-dependent RNA polymerase activity, addressing a broad spectrum of RNA viruses with precision and efficacy.
Broad-Spectrum Antiviral Activity
Effective Across High-Burden Pathogens
MDL-001 has demonstrated potent antiviral activity against a diverse array of RNA viruses, including:
SARS-CoV-2
hCoV-α
hCoV-β
Norovirus
Influenza A
Influenza B
HCV
This broad-spectrum efficacy positions MDL-001 as a vital tool for addressing both current pandemics and emerging viral threats.
First-in-Class
and Best-in-Class
Setting New Standards in Antiviral Activity
MDL-001 exhibits superior antiviral activity compared to current benchmarks:
17x more potent than Paxlovid
MDL-001 extends activity beyond SARS-CoV-2, targeting multiple RNA viruses with a single therapy.
100x more potent than Tenofovir
Addresses Hepatitis C while broadening therapeutic applicability.
Unmet Therapeutic Needs
Provides solutions where no approved antivirals exist, such as Norovirus and EBV.
Lung Partitioning
Enhanced Delivery to Critical Infection Sites
MDL-001 is uniquely optimized for significant lung partitioning, ensuring effective delivery to primary infection sites for respiratory viruses like SARS-CoV-2 and Influenza. This advanced pharmacokinetic property enhances therapeutic outcomes, particularly for respiratory diseases where localized antiviral activity is critical.
High Lung Concentration
Maximizes antiviral efficacy at the site of viral replication.
Sustained Activity
Long-lasting lung presence ensures extended therapeutic coverage with minimal dosing frequency.
Targeted Impact
Reduces systemic exposure, improving tolerability while focusing action where it’s needed most.
Bioavailability
Designed for Patient Accessibility
MDL-001’s optimized oral bioavailability ensures effective absorption, making it scalable and accessible for global use. This key attribute supports both preventative and therapeutic applications in diverse healthcare settings.
Safety and Tolerability
A Patient-Centric Solution
Extensive preclinical evaluations highlight MDL-001’s favorable safety profile:
Favorable Pharmacokinetic Profile
Efficiency Meets Precision
MDL-001 is characterized by:
Revolutionizing Antiviral Treatment
learn more
Partnerships
Join Us in Advancing Antiviral Innovation
Our pipeline is built on the foundation of bold science and transformative potential. We welcome partnerships to accelerate the development and deployment of these life-saving therapies.
Science